Last reviewed 2026-04-23 · How we verify

RTS,S/AS01

RTS,S/AS01 is a vaccine that protects against malaria by stimulating the body to produce antibodies against the Plasmodium falciparum parasite.

RTS,S/AS01 is a vaccine that protects against malaria by stimulating the body to produce antibodies against the Plasmodium falciparum parasite. Used for Malaria prevention in children.

At a glance

Mechanism of action

The vaccine works by introducing a weakened form of the parasite to the body, which triggers an immune response and the production of antibodies that can recognize and neutralize the parasite. This provides long-term protection against malaria, particularly in areas where the disease is common.

Approved indications

• Malaria prevention in children

Common side effects

• Injection site pain
• Fever
• Headache

Key clinical trials

• RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi
• Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa (PHASE4)
• Strengthening the Evidence for Policy on the RTS,S/AS01 Malaria Vaccine
• Study to Assess the Vaccine Efficacy Against Malaria Infection, in Children Immunized With the Primary and Yearly Booster of the RTS,S/AS01E Vaccine, as Part of Their Participation in the Malaria-094 (204889/NCT03276962) Study.
• Malaria Vaccine Pilot Evaluation
• Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study (PHASE3)
• Impact of Vaccines on Antimicrobial Microbial Resistance
• The Impact RTS,S/AS01 Vaccine in School Aged Children RTS,S/AS01 Malaria Vaccine in School Aged Children (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.